All In Biotech

Drug Trial Radar · NCT06928662

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Sep 23, 2025

Primary completion

Mar 9, 2028

Study completion Nov 29, 2028

Sponsor

Lead sponsor
Fred Hutchinson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell transplant in treating adult patients with cancers of blood-forming cells of the bone marrow (myeloid malignancies) that are at high risk of coming back after treatment (relapse). Cancers eligible for this trial are acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. The FLAG-Ida regimen consists of the following drugs: fludarabine, cytarabine, filgrastim, and idarubicin. These are chemotherapy drugs that work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Filgrastim is in a class of medications called colony-stimulating factors. It works by helping the body make more neutrophils, a type of white blood cell. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. TBI is radiation therapy to the entire body. Giving chemotherapy and TBI before a donor peripheral blood stem cell (PBSC) transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets. Giving decitabine in combination with FLAG-Ida and TBI before donor PBSC transplant may work better than FLAG-Ida and TBI alone in treating adult patients with myeloid malignancies at high risk of relapse.

Conditions

  • Acute Myeloid Leukemia
  • Acute Undifferentiated Leukemia
  • Mixed Phenotype Acute Leukemia
  • Recurrent Acute Myeloid Leukemia
  • Recurrent Acute Undifferentiated Leukemia
  • Recurrent Chronic Myelomonocytic Leukemia
  • Recurrent Mixed Phenotype Acute Leukemia
  • Recurrent Myelodysplastic Syndrome
  • Refractory Acute Myeloid Leukemia
  • Refractory Acute Undifferentiated Leukemia
  • Refractory Chronic Myelomonocytic Leukemia
  • Refractory Mixed Phenotype Acute Leukemia
  • Refractory Myelodysplastic Syndrome
  • Secondary Acute Myeloid Leukemia

Interventions

  • DecitabineDrug

    Given IV

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration and/or biopsies

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow aspiration and/or biopsies

  • Chest RadiographyProcedure

    Undergo chest X-rays

  • CytarabineDrug

    Given IV

  • Echocardiography TestProcedure

    Undergo ECHO

  • FilgrastimBiological

    Given SC

  • FludarabineDrug

    Given IV

  • Hematopoietic Cell TransplantationProcedure

    Given via infusion

  • IdarubicinDrug

    Given IV

  • Multigated Acquisition ScanProcedure

    Undergo MUGA

  • PheresisProcedure

    Undergo apheresis

  • Total-Body IrradiationRadiation

    Undergo TBI

  • Biospecimen CollectionProcedure

    Undergo collection of blood

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Non-relapse mortality (Phase 1)Time frame: At day 100
  2. Disease-free survival (Phase 2)Time frame: At 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.